Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 3

Conditions

Fungal Infection

Treatments

Drug: Posaconazole

Study type

Interventional

Funder types

Industry

Identifiers

NCT00811642

P05551

Details and patient eligibility

About

The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI

Enrollment

63 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must be 18-70 years male or female
Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.
Sign informed consent form

Exclusion criteria

Female participants who are pregnant or are nursing.
Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B
Participants with progressive nervous system diseases( excluding those IFI caused)
Participants who take the following drugs known with interference with azole antifungal preparations
- terfenadine, cisapride, and ebastine within 24 hours before entry
- astemizole at entry or within 10 days before entry
- cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry
The drugs listed above are prohibited during the investigation
Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate <60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.
Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.
Expected to take during investigation or is taking systemic antifungal treatment
Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are >2×ULN.
Participants expected to survive no more than 72hrs
Participants receiving artificial aeration and will not withdraw within 24hrs
Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.
Prior enrollment in this study.
History of alcohol and/or drug abuse.
Participants cannot be compliant in investigator's opinion.